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VOC 202012/01, a SARS-CoV-2 variant first detected in the United Kingdom in September 20 
2020, has spread to multiple countries worldwide. Several studies have established that 21 
this novel variant is more transmissible than preexisting variants, but have not identified 22 
whether it leads to any change in disease severity. We analyse a large database of SARS-23 
CoV-2 community test results and COVID-19 deaths, representing 52% of all SARS-CoV-2 24 
community tests in England from 1 September 2020 to 5 February 2021. This subset of 25 
SARS-CoV-2 tests can identify VOC 202012/01 because mutations in this lineage prevent 26 
PCR amplification of the spike gene target (S gene target failure, SGTF). We estimate that 27 
the hazard of death among SGTF cases is 58% (95% CI 40–79%) higher than among non-28 
SGTF cases after adjustment for age, sex, ethnicity, deprivation level, care home 29 
residence, local authority of residence and test date. This corresponds to the absolute 30 
risk of death for a male aged 55–69 increasing from 0.6% to 0.9% (95% CI 0.8–1.0%) over 31 
the 28 days following a positive test in the community. Correcting for misclassification of 32 
SGTF and missingness in SGTF status, we estimate a 71% (48–97%) higher hazard of 33 
death associated with VOC 202012/01. Our analysis suggests that VOC 202012/01 is not 34 
only more transmissible than preexisting SARS-CoV-2 variants but may also cause more 35 
severe illness. 36 
 37 
Most community SARS-CoV-2 PCR tests in England are processed by one of six national 38 
“Lighthouse” laboratories. Among the mutations carried by Variant of Concern (VOC) 202012/01 39 
is a 6-nucleotide deletion which prevents amplification of the S gene target by the commercial 40 
PCR assay used in three of the Lighthouse labs1. By linking individual records of positive 41 
community tests with and without S gene target failure (SGTF) to a comprehensive line list of 42 
COVID-19 deaths in England, we estimate the relative hazard of death associated with infection 43 
by VOC 202012/01. We define confirmed SGTF as a compatible PCR result with cycle 44 
threshold (Ct) < 30 for ORF1ab, Ct < 30 for N, and no detectable S (Ct > 40); confirmed non-45 
SGTF as any compatible PCR result with Ct < 30 for each of ORF1ab, N, and S; and an 46 
inconclusive (missing) result as any other positive community test, including tests processed by 47 
a laboratory incapable of assessing SGTF. We address missing SGTF status in our analysis.  48 
 49 
Characteristics of the study population 50 
 51 
The study sample (Table 1) includes a total of 1,994,449individuals who had a positive 52 
community (“Pillar 2”) test between 1 November 2020 and 25 January 2021. Just over half of 53 
those tested (1,028,296, 52%) had a conclusive SGTF reading and, of these, 48% had SGTF. 54 
Females comprised 53.7% of the total sample; 44.4% were aged 1–34 years, 34.3% aged 35–55 
54, 15.1% aged 55–69, 4.3% aged 70–85 and 1.9% aged 85 or older. The majority of 56 
individuals (93.7%) lived in residential accommodation (defined as residing in a house, flat, 57 
sheltered accommodation, or house in multiple occupancy), with 3.1% living in a care or nursing 58 
home. Based on self-identified ethnicity, 73.8% were White, 13.7% Asian, 4.7% Black and 7.8% 59 
of other, mixed or unknown ethnicity. The data include tests performed in all 7 NHS England 60 
regions, with the London region contributing 23.4% of tests and the South West 5.8%. The first 61 
two weeks of the study period (1–14 Nov) contributed 12.6% of the total tests, and the final two 62 
weeks (10–25 Jan) 22.2%. The period between 27 Dec and 9 Jan contributed 30.5% of tests. 63 
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 64 
In those with SGTF status measured, SGTF prevalence was similar in males and females but 65 
lower in the older age groups: 54.9% in the 1-34 year olds compared with 48.6% in those aged 66 
85 and older. In keeping with these age patterns, SGTF prevalence was lower in individuals 67 
living in a care or nursing home (45.2%, compared to 54.7% among those in residential 68 
accommodation). SGTF prevalence by self-identified ethnicity was 53.5% in the White group, 69 
54.0% in the Asian group, 67.2% in the Black group, and 61.6% in the other, mixed, or unknown 70 
ethnicity group. SGTF prevalence was lowest in the most deprived index of multiple deprivation1 71 
(IMD) decile (43.9%) and highest in the least deprived decile (58.7%). The highest prevalences 72 
of SGTF over the study period were observed in the East of England (75.7%), South East 73 
(75.6%) and London (74.0%) NHS England regions, and prevalence of SGTF was lowest in the 74 
North East and Yorkshire region (32.5%). The prevalence of SGTF also increased steeply over 75 
time (Fig. 1a), ranging from 4.9% during 1–14 November 2020 to 87.4% during 10 –25 January 76 
2021.  77 
 78 
Having missing SGTF status was strongly associated with age and place of residence. The 79 
proportion with SGTF status missing was similar in age groups 1-34 (47.9%), 35-54 (47.1%) 80 
and 55-69 (47.7%), and then rose to 54.3% in the 70-84 age group and to 78.6% in the 85 and 81 
older age group. SGTF status was missing in 89.1% of tests for individuals living in a care or 82 
nursing home, compared to 46.9% of tests among individuals in residential accommodation. 83 
This is partly due to more extensive use of lateral flow immunoassay tests in care homes, which 84 
do not yield an SGTF reading. Missingness in SGTF status also differed substantially by NHS 85 
England region, ranging from 21.5% in the North West to 70.8% in the South West. Missingness 86 
also depended on specimen date, with the percentage missing being lower for the earlier 87 
specimen dates and highest (55.4%) in the 2 week period that contributed the most tests (27 88 
December-9 January). There were also some more minor differences in the percentages of 89 
missingness of SGTF status by ethnicity and IMD. Of the 48% of tests with missing SGTF 90 
status, 9% were inconclusive due to high Ct values and the remaining 39% were not analysed in 91 
one of the three Lighthouse labs capable of producing an SGTF result. 92 
 93 
The most commonly used definition of a COVID-19 death in England is any death occurring 94 
within 28 days of a positive SARS-CoV-2 test. Table 2 presents crude death rates within 28 95 
days of a positive test per 10,000 person-days of follow-up. Death rates  for unlimited follow-up 96 
(i.e. not restricted to 28 days) are shown in Table S1; the maximum observed follow-up was 85 97 
days. A total of 13,860 individuals out of the 1,994,449 in the study sample are known to have 98 
died (0.69%), 12,967 of whom (92.8%) died within 28 days of their first positive test (Fig. 1b). 99 
As expected, crude death rates were substantially higher in the elderly and in those living in a 100 
care or nursing home. 101 
Crude survival assessed by Kaplan-Meier curves was lower in the SGTF group (Fig. 1c). 102 
Stratifying by broad age groups and looking at death rates by sex, place of residence, ethnicity, 103 
IMD, NHS England region, and specimen date, it can be seen that death rates within 28 days of 104 
a positive SARS-CoV-2 test are higher among SGTF than non-SGTF cases in 99 of the 108 105 
strata assessed (92%; Figs. 1d–i).  106 
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Fig. 1. Descriptive analyses. a The number of samples with and without SGTF by day from 1 November 110 
2020 to 25 January 2021, the period covered by our main analysis. b Number of deaths within 28 days of 111 
positive test by specimen date included in the analysis. c Kaplan-Meier plot showing survival among 112 
individuals tested in the community in England with and without SGTF, in the subset with SGTF 113 
measured. Inset shows the full y–axis range. d–i Crude death rates (with 95% confidence intervals) in 114 
SGTF and non-SGTF tests (in the subset with SGTF measured) for deaths within 28 days of positive test 115 
stratified by broad age groups and (d) sex, (e) place of residence, (f) ethnicity, (g) index of multiple 116 
deprivation, (h) NHS England region, and (i) specimen date. Dotted lines show the overall crude death 117 
rates by age group irrespective of SGTF status, with the shaded area showing the 95% CIs.  118 
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Cox regression analyses 119 
To estimate the effect of SGTF on mortality while controlling for observed confounding, we fitted 120 
a series of Cox proportional hazards models2 to the data. We stratified the analysis by lower tier 121 
local authority (LTLA) and specimen date to control for geographical and temporal differences in 122 
the baseline hazard—for example, due to changes in hospital pressure during the study 123 
period—and used spline terms for age and IMD and fixed effects for sex, ethnicity, and 124 
residence type. All models were fitted twice, once using complete cases only, i.e. by simply 125 
excluding individuals with missing SGTF status, and once using inverse probability weighting 126 
(IPW), i.e. accounting for missingness by upweighting individuals whose characteristics—age, 127 
sex, IMD, ethnicity, residence type, NHS England region of residence and sampling week—are 128 
underrepresented among complete cases.  129 
For the complete-cases analysis, the estimated hazard ratio for SGTF was 1.58 (95% CI 1.40–130 
1.79), indicating that the hazard of death within 28 days of a positive test is 58% (40–79%) 131 
higher in those with SGTF compared to non-SGTF (Fig. 2a). We included an interaction term 132 
between SGTF and time since positive test in the model to assess the proportional hazards 133 
assumption. There was strong evidence of non-proportionality of hazards (likelihood ratio test 134 
!(# !
" = 7.1) = 0.008; Fig. 2a; Fig. S11). The estimated time-varying hazard ratio increases 135 
over time: 1.19 (0.94–1.52) one day after the positive test, 1.66 (1.46–1.88) on day 14, and 2.36 136 
(1.71–3.25) on day 28. There was no evidence that adding higher-order functions of time into 137 
the interaction terms improved model fit (likelihood ratio test !(# !" = 1.0) = 0.32), and no 138 
evidence of a significant interaction between time and age (!(# !" = 0.03) = 0.87), time and 139 
sex (!(# !" = 3.6) = 0.056), time and IMD (!(# !" = 0.10) = 0.75), time and ethnicity (!(# #" =140 
1.4) = 0.71), or time and residence type (!(# "" = 1.5) = 0.47).  141 
We found no evidence of a significant interaction between SGTF and age group (likelihood ratio 142 
test !(# $" = 6.7) = 0.15), sex (!(# !" = 0.44) = 0.51), IMD (!(# %" = 5.0) = 0.84), or ethnicity 143 
(!(# #" = 0.95) = 0.81). There was some evidence of an interaction between SGTF and 144 
residence type (!(# "" = 6.8) = 0.034), with the associated hazard ratio for SGTF being 1.53 145 
(1.35–1.74) in standard residential accommodation , 2.43 (1.72–3.45) in care/nursing homes, 146 
and 1.64 (0.80–3.38) in “other” residence types (i.e. residential institutions including residential 147 
education, prisons and detention centres, medical facilities, no fixed abode and other/unknown). 148 
In the investigation of a model for the probability of missingness in SGTF status, the cauchit 149 
model was found to provide a good fit and to result in less extreme  weights than the logistic 150 
model. The IPW analysis was therefore performed using weights derived from the cauchit 151 
model. The IPW analysis yielded similar results to the complete-cases analysis, generally with 152 
marginally higher hazard ratios and wider CIs (Fig. 2e); the hazard ratio associated with SGTF 153 
for the IPW analysis was 1.67 (1.46–1.90). While the IPW analysis recovered a similarly time-154 
varying hazard ratio to the complete-cases analysis, the increase was less marked (Fig. 2c) and 155 
the inclusion of a time-varying term did not significantly improve model fit (Wald test!(# !" =156 
1.0) = 0.33).  157 
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 158 
Fig. 2. Survival analyses. a–d Estimated hazard ratio of death within 28 days of positive test for (a) 159 
SGTF, complete-cases analysis; (b) pVOC, complete-cases analysis; (c) SGTF, IPW analysis; and (d) 160 
pVOC, IPW analysis, in model stratified by LTLA and specimen date and adjusted for the other covariates. 161 
e Estimated hazard ratio of death within 28 days of positive test across each model investigated. Death 162 
types are coded as follows: dX, all deaths within X days of a positive test; c28, death-certificate-confirmed 163 
COVID-19 deaths within 28 days; e60, all deaths within 60 days plus all death-certificate-confirmed 164 
COVID-19 deaths within any time period. S, spline term (for Age or IMD); L, linear term (for Age or IMD); 165 
LTLA, lower-tier local authority (n = 316); UTLA, upper-tier local authority (n = 150); NHSE, NHS England 166 
region (n = 7). LTLA start date signifies a start date chosen separately for each LTLA (see Methods). 167 
Point estimates and 95% confidence intervals shown. 168 
  169 
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Misclassification analysis 170 
 171 
Prior to the emergence of VOC 202012/01, a number of minor circulating SARS-CoV-2 lineages 172 
with spike mutations could also cause SGTF3. Our main analyses are restricted to specimens 173 
from 1 November 2020 onwards to minimise the number of these non-VOC 202012/01 lineages 174 
among SGTF-positive samples. However, the appearance of non-VOC 202012/01 samples in 175 
SGTF may dilute the estimated effect of VOC 202012/01 on the hazard of mortality. We 176 
therefore undertook a misclassification analysis4, modelling the relative frequency of SGTF over 177 
time for each NHS England region as a combination of a low, time-invariant frequency of non-178 
VOC 202012/01 samples with SGTF plus a logistically growing5 frequency of VOC 202012/01 179 
samples with SGTF, which allows us to assign to each SGTF sample a probability pVOC that the 180 
sample is VOC 202012/01 based upon its specimen date and NHS England region (Fig. S9). 181 
Again restricting the analysis to specimens from 1 November 2020 onward, we find a hazard 182 
ratio associated with pVOC of 1.63 (1.44–1.86) for the complete-cases analysis and 1.71 (1.48–183 
1.97) for the IPW analysis. 184 
 185 
Absolute risks 186 
 187 
To put these results into context, we estimated how the absolute risk of death due to COVID-19 188 
may differ had an individual been infected with VOC 202012/01 compared with had they been 189 
infected with the original variant. We calculated absolute risks by applying 28--day hazard ratios 190 
for SGTF to the baseline risk of death estimated among individuals tested in the community 191 
between August–October 2020 (expected to be representative of the CFR associated with 192 
preexisting variants of SARS-CoV-2; Table 3). The risk of death due to COVID-19 following a 193 
positive test in the community remains below 1% in most individuals younger than 70 years old. 194 
For the complete cases analysis, in females aged 70–84, the estimated risk of death within 28 195 
days of a positive SARS-CoV-2 test with SGTF increases from 2.9% to 4.5% (95% CI 4.0–196 
5.1%) and for females 85 or older increases from 13% to 20% (17–22%). For males aged 70–84 197 
the risk of death within 28 days increases from 4.7% to 7.3% (6.4–8.2%) and for males 85 or 198 
older it increases from 17% to 26% (23–28%). Estimates based on the IPW analysis were 199 
marginally higher. These estimates reflect a substantial increase in absolute risk amongst older 200 
age groups. Note that these estimates do not reflect the infection fatality ratio, but the fatality 201 
ratio among people tested in the community, and are thus likely to be higher than the infection 202 
fatality rate as many infected individuals will not have been tested. 203 
 204 
Further investigations 205 
We conducted a number of sensitivity analyses to verify the robustness of our results. Our main 206 
results were largely insensitive to: restriction to death-certificate-confirmed COVID-19 deaths 207 
only; any follow-up time of 21 days or longer; coarseness of geographical and temporal 208 
stratification; use of linear versus spline terms for age and IMD; analysis start date; followup 209 
time–covariate interactions; removal of the 10-day death registration cutoff; and restriction of the 210 
analysis to individuals with a full 28-day follow-up period (Fig. 2e; Table S2). Pillar 2 testing 211 
data include an indicator for whether the subject was tested because of symptoms or due to 212 
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asymptomatic screening. Although symptomatic status may lie on the causal pathway between 213 
SGTF status and death, we adjusted for symptomatic status as a further sensitivity analysis and 214 




Our analysis identifies an increased hazard of death associated with VOC 202012/01 infection 219 
relative to infection by preexisting SARS-CoV-2 variants. We controlled for several factors that 220 
we hypothesised could confound the association between VOC 202012/01 infection status and 221 
mortality. By controlling for test time and geographical location, via stratified analysis, mimicking 222 
matching on these variables, we aimed to account for the fact that VOC 202012/01 infection 223 
increased rapidly over time and differed substantially by region, and also that the hospitals in 224 
which some individuals will have required care were subject to pressure on health services that 225 
changed over time and by region.   226 
 227 
We do not attempt to identify the mechanism for an increased mortality rate in this analysis. 228 
There is some evidence that infections with VOC 202012/01 may be associated with higher viral 229 
loads, as measured by Ct values detected during PCR testing of specimens (Fig. S10). Higher 230 
viral loads resulting from infection with VOC 202012/01 may be partly responsible for the 231 
observed increase in mortality, partly because they may reduce the efficacy of standard antiviral 232 
treatments for COVID-19. The impact of viral load on observed SGTF mortality could be 233 
assessed using a mediation analysis, which is outside the remit of this study. 234 
 235 
Another potential explanation for an increased mortality rate among individuals testing positive 236 
for VOC 202012/01 may be that this variant leads to changes in testing behaviour. If individuals 237 
infected with this variant are less likely to show symptoms, then only relatively more severe 238 
cases may get tested, and consequently our study would overestimate the infection fatality rate. 239 
However, comparison to random population testing carried out by the Office for National 240 
Statistics suggests no clear difference in the proportion of SGTF among Pillar 2 tests relative to 241 
the population at large (Fig. S12). 242 
 243 
We previously identified that the novel SARS-CoV-2 lineage VOC 202012/01 appears to have a 244 
substantially greater transmission rate than preexisting variants of SARS-CoV-25, but could not 245 
robustly estimate any increase or decrease in associated disease severity from ecological 246 
analysis. The individual-level linked community testing data analysed here suggest that the 247 
fatality rate among individuals infected with VOC 202012/01 is higher than that associated with 248 
infection by preexisting variants. Crucially, due to the nature of the data currently available, we 249 
were only able to assess mortality among individuals who received a positive test for SARS-250 
CoV-2 in the community. Indicators for VOC 202012/01 are not currently available for the vast 251 
majority of individuals who die due to COVID-19, as they are first tested in hospital. Accordingly, 252 
the evidence we provide here must be contextualised with further study of a larger population 253 
sample, and in other settings. Nonetheless, by focusing on individuals tested in the community, 254 
our analysis captures any combined effect of an altered risk of hospitalisation given positive test 255 
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and an altered risk of death given hospitalisation, which would not be fully captured by a study 256 
focusing on hospitalised patients only.  257 
 258 
Our findings are consistent with those identified  by other groups using different methods to 259 
verify the increased risk of death among community-tested individuals with SGTF6. Estimates of 260 
increased mortality based upon Pillar 2 data will become more robust as test results and 261 
mortality outcomes continue to accumulate over time. However, our approach of comparing 262 
outcomes between individuals with and without SGTF who were tested in the same place and at 263 
the same time would no longer accrue additional information at the point when SGTF becomes 264 
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Methods 272 
 273 
Data sources — We linked three datasets provided by Public Health England: a line list of all 274 
positive tests in England’s “Pillar 2” (community) testing for SARS-CoV-2, containing specimen 275 
date and demographic information on the test subject; a line list of cycle threshold (Ct) values 276 
for the ORF1ab, N (nucleocapsid), and S (spike) genes for positive tests that were processed in 277 
one of the three national laboratories (Alderley Park, Glasgow, or Milton Keynes) utilising the 278 
Thermo Fisher TaqPath COVID-19 assay; and a line list of all deaths due to COVID-19 in 279 
England, which combines and deduplicates deaths reported by hospitals in England, by the 280 
Office for National Statistics, via direct reporting from Public Health England Health Protection 281 
Team, and via Demographic Batch Service tracing of laboratory-confirmed cases 7. We link 282 
these datasets using a numeric identifier for Pillar 2 tests (‘FINALID’) common to all three 283 
datasets. We define S gene target failure (SGTF) as any test with Ct < 30 for ORF1ab and N 284 
targets but no detectable S gene, and non-SGTF as any test with Ct < 30 for ORF1ab, N, and S 285 
targets. A small proportion (9%) of SGTF tests are inconclusive. The study population of interest 286 
is defined as all individuals who received a positive Pillar 2 test between 1 November 2020 and 287 
25 January 2021. For our main analysis, we included only tests from after 1 November 2020 to 288 
avoid including an excess of tests with SGTF not resulting from infection by VOC 202012/01. In 289 
sensitivity analyses, we also consider extending the population to include tests performed 290 
between 1 September and 31 October 2020.. 291 
 292 
The linked dataset available for analysis excludes individuals who first tested positive in 293 
hospital, that is, those who presented to hospital after symptom onset without first being tested 294 
in the community. This is because cycle threshold values used to ascertain SGTF status are not 295 
available for individuals who were not tested in the community. Our study sample comprises all 296 
community tests between 1 November 2020 and 25 January 2021, but only 7% of the total 297 
number of COVID-19 deaths were recorded within 28 days following a positive test in either the 298 
community or in hospital during this period. This is explained by differing mortality rates among 299 
individuals who first test positive in a hospital compared to those who first receive a community 300 
test.  301 
 302 
There was a small amount of missing data for sex (n = 13, <0.01%), age (n = 151, <0.01%), and 303 
IMD and regional covariates (n = 3,428, 0.15%). There were no missing specimen dates. 304 
Individuals with missing age, sex, or geographical location were excluded. We also excluded 305 
individuals from the dataset whose age was recorded as zero, as there were 16,936 age-0 306 
individuals compared to 8,867 age-1 individuals in the dataset, suggesting that many of these 307 
age-0 individuals may have been miscoded. There was some missing data on ethnicity (n = 308 
43,032, 2%) and we created a category that combines missing values with “Other” and “Mixed”. 309 
Missing values for residence type (n = 67,458, 3%) were also combined with an “Other” 310 
category. The data set used for the main analysis comprises 1,994,449 individuals, and SGTF 311 
status is missing for 966,153 (48%). In addition, the SGTF status of 97,461 individuals (9%) with 312 
an inconclusive SGTF test was set to missing. Missing data on the exposure is addressed in the 313 
analysis, described below. 314 
 315 
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We grouped residence types into three categories: Residential, which included the “Residential 316 
dwelling (including houses, flats, sheltered accommodation)” and “House in multiple occupancy 317 
(HMO)” groups; Care/Nursing home; and Other/Unknown, which included the "Medical facilities 318 
(including hospitals and hospices, and mental health)", "No fixed abode", "Other property 319 
classifications", "Overseas address", "Prisons, detention centres, secure units", "Residential 320 
institution (including residential education)", and "Undetermined" groups, as well as unspecified 321 
residence type. We grouped ethnicities into four categories according to the broad categories 322 
used in the 2011 UK Census: Asian, which included the "Bangladeshi (Asian or Asian British)", 323 
"Chinese (other ethnic group)", "Indian (Asian or Asian British)", "Pakistani (Asian or Asian 324 
British)", and "Any other Asian background" groups; Black, which included the "African (Black or 325 
Black British)", "Caribbean (Black or Black British)", and "Any other Black background" groups; 326 
White, which included the "British (White)", "Irish (White)", and "Any other White background" 327 
groups; and Other / Mixed / Unknown, which included the "Any other ethnic group", "White and 328 
Asian (Mixed)", "White and Black African (Mixed)", "White and Black Caribbean (Mixed)", "Any 329 
other Mixed background", and "Unknown" groups. 330 
 331 
Statistical methods — There are several factors that we expect to be associated with both  332 
SGTF and with risk of death, thus confounding the association between SGTF and risk of death 333 
in those tested. Area of residence and specimen date were expected to be potentially strong 334 
confounders. Area of residence is expected to be strongly associated with SGTF status due to 335 
different virus variants circulating in different areas, and specimen date because the prevalence 336 
of SGTF is known to have greatly increased over time. Area of residence and specimen date 337 
are also expected to be associated with risk of death following a test, including due to  338 
differential pressure on hospital resources by area and time. The following variables were also 339 
identified as potential confounders: sex, age, place of residence (Residential, Care/Nursing 340 
home, or Other/Unknown), ethnicity (White, Asian, Black, or Other/Mixed/Unknown), index of 341 
multiple deprivation (IMD). The potential confounders are referred to collectively as the 342 
covariates. For descriptive analyses, age (in years) was categorised as 1-34, 35-54, 55-69, 70-343 
84, 85 and older. 344 
 345 
Descriptive analyses were performed. We tabulated the distribution of the covariates in the 346 
whole study sample, and the association between each covariate and SGTF status in the 347 
subset with SGTF measured (Table 1). We also summarised the association between each 348 
covariate and missing data in SGTF status (Table 1). The subset with SGTF status measured 349 
are referred to as the complete cases. The unadjusted association between SGTF and mortality 350 
in the complete cases was assessed using a Kaplan-Meier plot (Fig. 1c) , and Kaplan-Meier 351 
plots and crude mortality rates (Table 2) are also presented separately according to categories 352 
of the covariates (Figs. S1–S7). Crude overall mortality rates were obtained for the whole 353 
sample, by SGTF status in the complete cases, and and in those with missing SGTF status, 354 
according to categories of each covariate (Table 2). We also obtained mortality rates by SGTF 355 
status (in the complete cases) for categories of each covariate stratified by age group. Exact 356 
Poisson CIs are used for mortality rates, assuming constant rate. 357 
 358 
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Approximately 46% of individuals in the study sample are missing data on SGTF status, due to 359 
their test not being sent to one of the three laboratories utilising the Thermo Fisher TaqPath 360 
COVID-19 assay or the test being inconclusive. We performed complete cases analysis, 361 
restricted to the subset with SGTF status measured. This complete case analysis assumes that 362 
for each analysis, the missing data, in this case missing SGTF status, is independent from the 363 
outcome of interest, given the variables included in the models. This is a specific type of Missing 364 
not at random assumption, as in particular it is allowed to depend on the underlying value of 365 
SFTG.  We also performed an analysis of the complete cases using inverse probability weights8 366 
(IPW) to address the missing data on SGTF, under a missing at random assumption (MAR). In 367 
the analysis, each individual with SGTF status measured is weighted by the inverse of their 368 
probability of having  SGTF status measured  based on their covariates. For the IPW, the 369 
missingness model estimated the probability of missingness using logistic regression with age 370 
(restricted cubic spline), sex , IMD decile (restricted cubic spline), ethnicity , residence type , 371 
and NHS region by specimen week as predictors. We also considered  a cauchit and a Gosset 372 
link for the missingness model, including the same predictors, as this was expected to provide 373 
better stability for the weights9. The fit of the missingness model was assessed using a Q-Q plot 374 
(Fig. S11), and Hosmer-Lemeshow and Hinkley tests were used to choose the most appropriate 375 
model. 376 
 377 
Cox regression2 was used to estimate the association between SGTF and the hazard for 378 
mortality, conditioning on the potential confounders listed above. The analyses described here 379 
were applied to the complete cases and using IPW, For IPW analyses, the standard errors 380 
(SEs) accounted for the weights, though the fact that the weights were estimated was not 381 
accounted for. This results in conservative SEs. The baseline hazard in the Cox model was 382 
stratified by both specimen date and LTLA, therefore finely controlling for these variables. The 383 
stratification gives a large number of strata matched by specimen date and LTLA. Only those 384 
strata that contain individuals who die and individuals who survive contribute to the analysis. 385 
The analysis is therefore similar to that which would be performed had we created a matched 386 
nested case-control sample. The remaining variables were included as covariates in the model 387 
(sex, age, place of residence, ethnicity, IMD decile). Age and IMD were included as restricted 388 
cubic splines with 3 knots. The time origin for the analysis was specimen date and we 389 
considered deaths up to 28 days after the specimen date. Individuals who did not die within 28 390 
days were censored at the earlier of 28 days post specimen date and the administrative 391 
censoring date, which we chose as the date of the most recent death linkable to SGTF status 392 
minus 10 days (i.e., 25 January 2021) in order to minimise any potential bias due to late 393 
reporting of deaths. We began by assuming proportionality of hazards for SGTF and the 394 
covariates included in the model. The proportional hazards assumption was assessed by 395 
including in the model an interaction between each covariate and time, which was performed 396 
separately for SGTF and for each other covariate. Schoenfeld residual plots were also obtained 397 
for each covariate (Fig. S8). We assessed whether the association between SGTF and the 398 
hazard was modified by age, sex, IMD, ethnicity, and place of residence. Models with and 399 
without interactions were compared using likelihood ratio tests for the complete cases analyses. 400 
For the analysis using IPW we used Wald tests based on robust standard errors10.  401 
 402 
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The analysis assumes that censoring is uninformative, which is plausible as all censoring is 403 
administrative.  404 
 405 
Misclassification analysis — The exposure of SGTF is subject to misclassification, because a 406 
number of minor circulating variants of SARS-CoV-2 in addition to VOC 202012/01 are also 407 
associated with failure to amplify the spike gene target. Accordingly, a positive test with SGTF is 408 
not necessarily indicative of infection with VOC 202012/01. A negative test of SGTF is assumed 409 
to be indicative of absence of infection with VOC 202012/01. Misclassification of an exposure 410 
can result in bias in its estimated association with the outcome. We fitted a logistic model to 411 
Pillar 2 SGTF frequencies by NHS region to estimate a “background” rate of SGTF in the 412 
absence of VOC 202012/01, assuming a beta binomial prior. This model is then used to 413 
estimate the probability that an individual testing positive with SGTF is infected with VOC 414 
202012/01, separately for individuals in each NHS region. These probabilities can then be used 415 
in place of the indicator of  SGTF exposure in the Cox models.  This is the regression calibration 416 
approach4 to correcting for bias due to measurement error in an exposure. .  417 
 418 
We fitted models accounting for false positives (modelled as regionally-varying background 419 
rates of SGTF associated with non-VOC 202012/01 variants) to the SGTF data. Our logistic 420 
model for VOC 202012/01 growth over time is as follows: 421 
 422 
12345	(7(5)) = (8129: × (5 − 4=5:>?:95)) 423 
8(5) = 7(5) + (1 − 7(5)) × 7A18:928 424 
B& ∼ D:5AE4=2F4A1(= = =& , H = 8(5) × (?2=? − 2) + 1, I = (1 − 8(5)) × (?2=? − 2) + 1) 425 
8129: ∼ =2>FA1(J = 0, K = 1) 426 
4=5:>?:95 ∼ =2>FA1(J = 0, K = 1000) 427 
7A18:928 ∼ D:5A(H = 1.5, I = 15) 428 
?2=? ∼ =2>FA1(J = 0, K = 500) ≥ 2 429 
 430 
Here, f(t) is the predicted frequency of VOC 202012/01 among positive tests at time t (in days 431 
since 1 September 2020) based on the terms slope and intercept; s(t) is the predicted frequency 432 
of S gene target failure at time t due to the combination of VOC 202012/01 and a background 433 
false positive rate falsepos, conc is the “concentration” parameter (= α + β) of a beta distribution 434 
with mode s(t); kt is the number of S gene target failures detected at time t; and nt is the total 435 
number of tests at time t. All priors above are chosen to be vague, and the truncation of conc to 436 
values greater than 2 ensures a unimodal distribution for the proportion of tests that are SGTF. 437 
The model above is fitted separately for each NHS England region. Then, pVOC for a test with 438 
SGTF = 1 at time t is equal to 7(5)/8(5), and pVOC = 0 for all tests with SGTF = 0. 439 
 440 
The model above was fitted using the same data source (i.e. SGTF frequencies among Pillar 2 441 
community tests for SARS-CoV-2) as our survival analysis. To verify the robustness of this 442 
model, we performed a sensitivity analysis using sequencing data from the COVID-19 UK 443 
Genomics Consortium11 downloaded from the Microreact platform12 on 11 January 2020 to 444 
estimate pVOC. In this alternative analysis we estimated pVOC for each NHS England region and 445 
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date as the number of samples that were VOC 202012/01 (i.e. lineage B.1.1.7 with mutations 446 
∆69/∆70 and N501Y in Spike) divided by the number of samples that were SGTF (i.e. any 447 
lineage with ∆69/∆70, the deletion that causes SGTF) for that NHS England region and date, 448 
setting pVOC = 1 for all dates later than 31 December 2020 as there were no sequencing data 449 
available past this date, and filling any gaps in the data using linear interpolation. This yielded 450 
nearly identical results to our modelled probability of VOC (Fig. 2e). 451 
 452 
Absolute risks — Estimates from the final Cox models were used to obtain estimates of absolute 453 
risk of death for 28 and 60 days with SGTF and pVOC. Given the strong influence of age on risk 454 
of death, we present absolute risks by sex and age group (1-34, 35-54, 55-69, 70-84, 85+). 455 
Absolute risks of death (case fatality rate) within 28 and 60 days were estimated by age group 456 
and sex using data on individuals tested during September 2020; this is referred to as the 457 
baseline risk. The absolute risks of death for individuals with SGTF were then estimated as 458 
follows. If the baseline absolute risk of death in a given age group is (1 − N), then the estimated 459 
absolute risk of death with SGTF is (1 − N'(	), where HR denotes the estimated hazard ratio 460 
obtained from the Cox model assuming proportional hazards.  We applied the hazard ratio from 461 
28 days to the baseline risk for 28 days, and the hazard ratio for 60 days to the baseline risk for 462 
60 days, to estimate absolute risks of death for individuals with SGTF and uncertainty of these 463 
estimates. Standard errors are obtained via the delta method, and CIs based on normal 464 
approximations.  465 
 466 
Sensitivity analyses — Several sensitivity analyses were performed. After establishing the final 467 
model through using the process outlined above we investigated the impact of using different 468 
variables for stratification of the baseline hazard measuring region at a coarser level (UTLA, or 469 
NHS England region), as well as coarser test specimen time (week rather than exact date). 470 
Adjusting for these variables instead of using stratification was also explored. We also repeated 471 
the main analysis restricting data to specimens collected from September onwards, October 472 
onwards, November onwards, or December onwards. 473 
To assess the impact of imposing an administrative cutoff to follow-up time of 10 days prior to 474 
data extraction, we first reanalysed the data without this cutoff, as well as reanalysing the data 475 
restricting the analysis to individuals with at least 28 days’ follow-up. 476 
Finally, we adjusted for symptomatic status associated withthe test (asymptomatic, 477 
symptomatic, or unknown), which relates to whether the test was given for asymptomatic 478 
screening purposes or on the basis of a request by a (presumed symptomatic) individual, as 479 
only symptomatic individuals may request a community SARS-CoV-2 test in England. 480 
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Tables 573 
 574 
Table 1. Characteristics of study subjects, 1 November 2020–25 January 2021. 575 
 576 

















N with SGTF/Total 




N with missing 
SGTF status/Total 
(%) 








562,282 / 1,028,296 
(54.7%) 
966,153 / 1,994,449 
(48.4%) 
Sex       








291,479 / 538,474 
(54.1%) 
533,309 / 1,071,783 
(49.8%) 








270,803 / 489,822 
(55.3%) 
432,844 / 922,666 
(46.9%) 
Age in years       








253,832 / 462,000 
(54.9%) 
424,034 / 886,034 
(47.9%) 








201,019 / 361,982 
(55.5%) 
322,780 / 684,762 
(47.1%) 








84,213 / 156,961 
(53.7%) 
143,368 / 300,329 
(47.7%) 






19,372 / 39,435 
(49.1%) 
46,885 / 86,320 
(54.3%) 




3,846 / 7,918 
(48.6%) 
29,086 / 37,004 
(78.6%) 
Place of residence       








542,875 / 992,071 
(54.7%) 
876,831 / 1,868,902 
(46.9%) 






3,027 / 6,699 
(45.2%) 
54,681 / 61,380 
(89.1%) 






16,380 / 29,526 
(55.5%) 
34,641 / 64,167 
(54%) 
Ethnicity       








410,447 / 767,163 
(53.5%) 
704,038 / 1,471,201 
(47.9%) 








80,133 / 148,422 
(54%) 
124,762 / 273,184 
(45.7%) 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted February 11, 2021. ; https://doi.org/10.1101/2021.02.01.21250959doi: medRxiv preprint 






27,480 / 40,878 
(67.2%) 
52,970 / 93,848 
(56.4%) 








44,222 / 71,833 
(61.6%) 
84,383 / 156,216 
(54%) 
Index of Multiple Deprivation 
decile 
      








57,280 / 130,426 
(43.9%) 
75,437 / 205,863 
(36.6%) 








65,777 / 124,996 
(52.6%) 
113,291 / 238,287 
(47.5%) 








67,143 / 120,668 
(55.6%) 
119,894 / 240,562 
(49.8%) 








62,722 / 109,464 
(57.3%) 
111,768 / 221,232 
(50.5%) 








58,259 / 101,095 
(57.6%) 
105,116 / 206,211 
(51%) 








54,158 / 94,262 
(57.5%) 
99,921 / 194,183 
(51.5%) 








51,572 / 91,997 
(56.1%) 
92,220 / 184,217 
(50.1%) 
    8 179,610 (9%) 88,611 
(9.2%) 
50,386 (9%) 40,613 
(8.7%) 
50,386 / 90,999 
(55.4%) 
88,611 / 179,610 
(49.3%) 






37,397 (8%) 49,511 / 86,908 
(57%) 
85,417 / 172,325 
(49.6%) 








45,474 / 77,481 
(58.7%) 
74,478 / 151,959 
(49%) 
NHS England region       








68,444 / 90,356 
(75.7%) 
160,554 / 250,910 
(64%) 








139,622 / 188,658 
(74%) 
278,708 / 467,366 
(59.6%) 








90,121 / 202,868 
(44.4%) 
161,896 / 364,764 
(44.4%) 








60,552 / 186,433 
(32.5%) 
53,697 / 240,130 
(22.4%) 








77,642 / 181,469 
(42.8%) 
49,691 / 231,160 
(21.5%) 








109,297 / 144,574 
(75.6%) 
179,493 / 324,067 
(55.4%) 
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16,604 (3%) 17,334 
(3.7%) 
16,604 / 33,938 
(48.9%) 
82,114 / 116,052 
(70.8%) 
Specimen date       
    1 Nov–14 Nov 251,389 
(12.6%) 




8,027 / 164,435 
(4.9%) 
86,954 / 251,389 
(34.6%) 
    15 Nov–28 Nov 168,861 
(8.5%) 




12,236 / 111,167 
(11%) 
57,694 / 168,861 
(34.2%) 








37,890 / 104,823 
(36.1%) 
61,600 / 166,423 
(37%) 








111,237 / 169,316 
(65.7%) 
186,943 / 356,259 
(52.5%) 








211,717 / 271,217 
(78.1%) 
336,667 / 607,884 
(55.4%) 








181,175 / 207,338 
(87.4%) 
236,295 / 443,633 
(53.3%) 
 577 
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Table 2. Rates of death within 28 days of positive test among study subjects. Total 579 
number of deaths, number of days of followup, and deaths per 10,000 days of followup 580 
reported. 581 
 582 
  All Missing SGTF  
status 
SGTF Non-SGTF 
     12,790 / 43,774,085 
(2.92) 
9,408 / 20,572,452 
(4.57) 
1,722 / 10,961,652 
(1.57) 
1,660 / 12,239,982 
(1.36) 
Sex     
    Female 6,733 / 23,564,628 
(2.86) 
5,293 / 11,396,647 
(4.64) 
714 / 5,682,724 (1.26) 726 / 6,485,256 (1.12) 
    Male 6,057 / 20,209,458 (3) 4,115 / 9,175,804 
(4.48) 
1,008 / 5,278,928 
(1.91) 
934 / 5,754,726 (1.62) 
Age     
    1–34 50 / 19,706,054 (0.03) 20 / 9,177,761 (0.02) 16 / 5,026,025 (0.03) 14 / 5,502,268 (0.03) 
    35–54 512 / 15,077,156 (0.34) 244 / 6,891,346 (0.35) 165 / 3,947,176 (0.42) 103 / 4,238,634 (0.24) 
    55–69 1,533 / 6,490,368 
(2.36) 
775 / 3,011,166 (2.57) 454 / 1,583,118 (2.87) 304 / 1,896,083 (1.6) 
    70–84 4,364 / 1,818,684 (24) 3,025 / 956,804 
(31.62) 
656 / 351,155 (18.68) 683 / 510,724 (13.37) 
    85 and older 6,331 / 681,824 (92.85) 5,344 / 535,374 
(99.82) 
431 / 54,177 (79.55) 556 / 92,272 (60.26) 
Place of residence     
    Residential 4,890 / 41,205,718 
(1.19) 
2,271 / 18,777,676 
(1.21) 
1,422 / 10,615,334 
(1.34) 
1,197 / 11,812,709 
(1.01) 
    Care/Nursing home 7,664 / 1,202,997 
(63.71) 
6,941 / 1,081,248 
(64.19) 
279 / 39,006 (71.53) 444 / 82,744 (53.66) 
    Other/Unknown 236 / 1,365,370 (1.73) 196 / 713,528 (2.75) 21 / 307,312 (0.68) 19 / 344,530 (0.55) 
Ethnicity     
    White 11,340 / 32,415,402 
(3.5) 
8,557 / 15,118,520 
(5.66) 
1,370 / 7,959,838 
(1.72) 
1,413 / 9,337,044 
(1.51) 
    Asian 887 / 6,020,388 (1.47) 472 / 2,630,158 (1.79) 236 / 1,569,368 (1.5) 179 / 1,820,862 (0.98) 
    Black 227 / 1,960,509 (1.16) 137 / 1,065,071 (1.29) 63 / 544,514 (1.16) 27 / 350,924 (0.77) 
    Other/Mixed/Unknown 336 / 3,377,786 (0.99) 242 / 1,758,702 (1.38) 53 / 887,932 (0.6) 41 / 731,152 (0.56) 
Index of Multiple Deprivation 
decile 
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    1 1,211 / 4,415,279 
(2.74) 
666 / 1,572,214 (4.24) 223 / 949,311 (2.35) 322 / 1,893,754 (1.7) 
    2 1,284 / 5,142,166 (2.5) 848 / 2,362,174 (3.59) 213 / 1,229,998 (1.73) 223 / 1,549,994 (1.44) 
    3 1,266 / 5,223,651 
(2.42) 
886 / 2,522,071 (3.51) 177 / 1,295,302 (1.37) 203 / 1,406,278 (1.44) 
    4 1,381 / 4,793,728 
(2.88) 
1,034 / 2,348,872 
(4.4) 
197 / 1,217,608 (1.62) 150 / 1,227,248 (1.22) 
    5 1,341 / 4,515,820 
(2.97) 
1,060 / 2,227,180 
(4.76) 
160 / 1,159,819 (1.38) 121 / 1,128,821 (1.07) 
    6 1,346 / 4,257,826 
(3.16) 
1,025 / 2,122,558 
(4.83) 
182 / 1,079,483 (1.69) 139 / 1,055,786 (1.32) 
    7 1,256 / 4,088,424 
(3.07) 
995 / 1,988,609 (5) 141 / 1,033,880 (1.36) 120 / 1,065,936 (1.13) 
    8 1,284 / 4,006,295 (3.2) 991 / 1,921,732 (5.16) 161 / 1,014,684 (1.59) 132 / 1,069,878 (1.23) 
    9 1,308 / 3,878,992 
(3.37) 
1,045 / 1,864,794 
(5.6) 
132 / 1,023,407 (1.29) 131 / 990,790 (1.32) 
    10 1,113 / 3,451,904 
(3.22) 
858 / 1,642,247 (5.22) 136 / 958,161 (1.42) 119 / 851,496 (1.4) 
NHS England region     
    East of England 1,783 / 5,511,951 
(3.23) 
1,527 / 3,471,280 
(4.4) 
183 / 1,455,449 (1.26) 73 / 585,222 (1.25) 
    London 1,426 / 10,377,194 
(1.37) 
1,073 / 5,914,652 
(1.81) 
281 / 3,127,714 (0.9) 72 / 1,334,828 (0.54) 
    Midlands 2,615 / 7,840,529 
(3.34) 
1,868 / 3,284,336 
(5.69) 
326 / 1,575,152 (2.07) 421 / 2,981,042 (1.41) 
    North East and Yorkshire 1,729 / 5,542,494 
(3.12) 
858 / 1,228,923 (6.98) 271 / 1,000,771 (2.71) 600 / 3,312,800 (1.81) 
    North West 1,318 / 4,904,162 
(2.69) 
713 / 1,116,972 (6.38) 259 / 1,157,800 (2.24) 346 / 2,629,389 (1.32) 
    South East 2,801 / 7,142,670 
(3.92) 
2,391 / 3,859,346 
(6.2) 
336 / 2,341,873 (1.43) 74 / 941,450 (0.79) 
    South West 1,118 / 2,455,085 
(4.55) 
978 / 1,696,942 (5.76) 66 / 302,894 (2.18) 74 / 455,250 (1.63) 
Specimen date     
    1 Nov–14 Nov 1,449 / 7,017,250 
(2.06) 
907 / 2,420,610 (3.75) 20 / 224,495 (0.89) 522 / 4,372,145 (1.19) 
    15 Nov–28 Nov 1,257 / 4,708,381 
(2.67) 
922 / 1,600,898 (5.76) 25 / 342,278 (0.73) 310 / 2,765,204 (1.12) 
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    29 Nov–12 Dec 1,402 / 4,638,356 
(3.02) 
1,013 / 1,708,928 
(5.93) 
124 / 1,059,364 (1.17) 265 / 1,870,064 (1.42) 
    13 Dec–26 Dec 2,078 / 9,944,324 
(2.09) 
1,514 / 5,211,339 
(2.91) 
349 / 3,110,010 (1.12) 215 / 1,622,976 (1.32) 
    27 Dec–9 Jan 4,706 / 13,706,868 
(3.43) 
3,636 / 7,635,678 
(4.76) 
814 / 4,709,516 (1.73) 256 / 1,361,674 (1.88) 
    10 Jan–25 Jan 1,898 / 3,758,906 
(5.05) 
1,416 / 1,994,996 
(7.1) 
390 / 1,515,990 (2.57) 92 / 247,919 (3.71) 
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Table 3. Absolute 28-day mortality risk associated with SGTF, as expressed by case 585 
fatality ratio (%) among individuals testing positive in the community. The baseline (i.e. 586 
original variant) absolute risk after 28 days post-test is derived using linked deaths for all 587 
individuals testing positive in the community from 1 August – 31 October 2020. Results 588 
presented for both complete cases and IPW analysis. 589 
 590 
Sex Age Baseline CFR Variant CFR (complete 
cases) 
Variant CFR (IPW) 
Female 0-34 0.00069% 0.0011% (0.00096-0.0012) 0.0012% (0.001-0.0013) 
Female 35-54 0.033% 0.052% (0.045-0.058) 0.054% (0.047-0.062) 
Female 55-69 0.18% 0.29% (0.25-0.32) 0.3% (0.26-0.34) 
Female 70-84 2.9% 4.5% (4-5.1) 4.7% (4.1-5.4) 
Female 85 and older 13% 20% (17-22) 20% (18-23) 
Male 0-34 0.0031% 0.0048% (0.0042-0.0055) 0.0051% (0.0044-0.0058) 
Male 35-54 0.063% 0.099% (0.087-0.11) 0.1% (0.09-0.12) 
Male 55-69 0.56% 0.88% (0.77-0.99) 0.93% (0.8-1) 
Male 70-84 4.7% 7.3% (6.4-8.2) 7.6% (6.7-8.6) 
Male 85 and older 17% 26% (23-28) 27% (24-30) 
 591 
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Supplementary tables 593 
 594 
Table S1. Rates of death within any time period following positive test among study 595 
subjects, including missing SGTF status. Total number of deaths, number of days of 596 
followup, and deaths per 10,000 days of followup reported. 597 
 598 
  All Missing SGTF Non-SGTF 
     13,860 / 69,160,118 (2) 10,127 / 29,806,446 
(3.4) 
1,785 / 13,504,310 
(1.32) 
1,948 / 25,849,361 
(0.75) 
Sex     
    Female 7,314 / 37,253,988 
(1.96) 
5,729 / 16,563,712 
(3.46) 
734 / 7,008,795 (1.05) 851 / 13,681,482 
(0.62) 
    Male 6,546 / 31,906,130 
(2.05) 
4,398 / 13,242,734 
(3.32) 
1,051 / 6,495,516 
(1.62) 
1,097 / 12,167,880 
(0.9) 
Age     
    1–34 55 / 31,260,216 (0.02) 20 / 13,348,169 (0.01) 16 / 6,266,754 (0.03) 19 / 11,645,294 (0.02) 
    35–54 570 / 23,686,455 (0.24) 262 / 9,887,338 (0.26) 176 / 4,861,304 (0.36) 132 / 8,937,812 (0.15) 
    55–69 1,712 / 10,271,464 
(1.67) 
838 / 4,359,417 (1.92) 480 / 1,898,842 (2.53) 394 / 4,013,205 (0.98) 
    70–84 4,724 / 2,899,684 
(16.29) 
3,269 / 1,410,603 
(23.17) 
673 / 415,546 (16.2) 782 / 1,073,534 (7.28) 
    85 and older 6,799 / 1,042,298 
(65.23) 
5,738 / 800,919 
(71.64) 
440 / 61,864 (71.12) 621 / 179,516 (34.59) 
Place of residence     
    Residential 5,344 / 64,971,901 
(0.82) 
2,429 / 26,956,788 
(0.9) 
1,475 / 13,075,518 
(1.13) 
1,440 / 24,939,596 
(0.58) 
    Care/Nursing home 8,271 / 2,010,503 
(41.14) 
7,495 / 1,800,672 
(41.62) 
287 / 46,928 (61.16) 489 / 162,904 (30.02) 
    Other/Unknown 245 / 2,177,714 (1.13) 203 / 1,048,988 (1.94) 23 / 381,865 (0.6) 19 / 746,862 (0.25) 
Ethnicity     
    White 12,289 / 51,755,410 
(2.37) 
9,218 / 22,149,052 
(4.16) 
1,416 / 9,840,646 
(1.44) 
1,655 / 19,765,712 
(0.84) 
    Asian 964 / 9,523,947 (1.01) 500 / 3,775,242 (1.32) 249 / 1,903,515 (1.31) 215 / 3,845,190 (0.56) 
    Black 242 / 2,813,798 (0.86) 143 / 1,438,408 (0.99) 66 / 662,912 (1) 33 / 712,478 (0.46) 
    Other/Mixed/Unknown 365 / 5,066,964 (0.72) 266 / 2,443,744 (1.09) 54 / 1,097,238 (0.49) 45 / 1,525,982 (0.29) 
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Index of Multiple Deprivation 
decile 
    
    1 1,346 / 7,642,162 
(1.76) 
742 / 2,532,840 (2.93) 229 / 1,104,186 (2.07) 375 / 4,005,136 (0.94) 
    2 1,412 / 8,218,058 
(1.72) 
923 / 3,439,324 (2.68) 224 / 1,492,162 (1.5) 265 / 3,286,572 (0.81) 
    3 1,362 / 8,143,723 
(1.67) 
948 / 3,584,962 (2.64) 182 / 1,593,884 (1.14) 232 / 2,964,876 (0.78) 
    4 1,484 / 7,437,915 (2) 1,108 / 3,352,900 
(3.3) 
202 / 1,498,640 (1.35) 174 / 2,586,375 (0.67) 
    5 1,453 / 6,998,806 
(2.08) 
1,134 / 3,179,536 
(3.57) 
170 / 1,447,943 (1.17) 149 / 2,371,327 (0.63) 
    6 1,442 / 6,598,334 
(2.19) 
1,095 / 3,035,862 
(3.61) 
185 / 1,343,834 (1.38) 162 / 2,218,638 (0.73) 
    7 1,383 / 6,420,691 
(2.15) 
1,083 / 2,874,795 
(3.77) 
145 / 1,289,344 (1.12) 155 / 2,256,552 (0.69) 
    8 1,366 / 6,290,169 
(2.17) 
1,047 / 2,768,153 
(3.78) 
168 / 1,260,494 (1.33) 151 / 2,261,522 (0.67) 
    9 1,410 / 6,051,438 
(2.33) 
1,122 / 2,679,682 
(4.19) 
138 / 1,277,721 (1.08) 150 / 2,094,036 (0.72) 
    10 1,202 / 5,358,822 
(2.24) 
925 / 2,358,393 (3.92) 142 / 1,196,100 (1.19) 135 / 1,804,328 (0.75) 
NHS England region     
    East of England 1,867 / 7,696,944 
(2.43) 
1,586 / 4,694,240 
(3.38) 
191 / 1,818,968 (1.05) 90 / 1,183,736 (0.76) 
    London 1,518 / 14,484,721 
(1.05) 
1,127 / 7,683,234 
(1.47) 
303 / 4,019,058 (0.75) 88 / 2,782,428 (0.32) 
    Midlands 2,900 / 13,471,944 
(2.15) 
2,063 / 5,496,554 
(3.75) 
331 / 1,772,414 (1.87) 506 / 6,202,975 (0.82) 
    North East and Yorkshire 1,954 / 10,587,604 
(1.85) 
981 / 2,121,664 (4.62) 276 / 1,159,505 (2.38) 697 / 7,306,436 (0.95) 
    North West 1,475 / 8,495,294 
(1.74) 
811 / 1,790,338 (4.53) 265 / 1,241,257 (2.13) 399 / 5,463,698 (0.73) 
    South East 2,955 / 10,426,000 
(2.83) 
2,517 / 5,320,110 
(4.73) 
353 / 3,131,366 (1.13) 85 / 1,974,524 (0.43) 
    South West 1,191 / 3,997,611 
(2.98) 
1,042 / 2,700,304 
(3.86) 
66 / 361,742 (1.82) 83 / 935,566 (0.89) 
Specimen date     
    1 Nov–14 Nov 1,846 / 19,613,076 
(0.94) 
1,159 / 6,742,156 
(1.72) 
24 / 621,195 (0.39) 663 / 12,249,725 
(0.54) 
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    15 Nov–28 Nov 1,533 / 10,949,347 
(1.4) 
1,118 / 3,709,086 
(3.01) 
32 / 780,457 (0.41) 383 / 6,459,804 (0.59) 
    29 Nov–12 Dec 1,625 / 8,237,496 
(1.97) 
1,166 / 3,025,100 
(3.85) 
141 / 1,843,366 (0.76) 318 / 3,369,030 (0.94) 
    13 Dec–26 Dec 2,251 / 12,857,434 
(1.75) 
1,631 / 6,680,294 
(2.44) 
384 / 4,020,394 (0.96) 236 / 2,156,746 (1.09) 
    27 Dec–9 Jan 4,707 / 13,743,859 
(3.42) 
3,637 / 7,654,812 
(4.75) 
814 / 4,722,910 (1.72) 256 / 1,366,137 (1.87) 
    10 Jan–25 Jan 1,898 / 3,758,906 
(5.05) 
1,416 / 1,994,996 
(7.1) 
390 / 1,515,990 (2.57) 92 / 247,919 (3.71) 
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Table S2. Hazard ratios for SGTF / VOC across models. 
 
 parameter HR 95% LCL 95% UCL Death type Marker Age term IMD term start date end date reg. cutoff (days) strata xvars weighting 
Death type               
 sgtf 1.61 1.42 1.84 c28 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.64 1.42 1.88 c28 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.25 0.99 1.58 d07 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.57 1.18 2.08 d07 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.40 1.20 1.62 d14 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.55 1.32 1.83 d14 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.54 1.35 1.76 d21 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.66 1.44 1.92 d21 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.67 1.46 1.90 d28 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.54 1.37 1.74 d60 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.64 1.43 1.87 d60 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.54 1.37 1.74 dNA SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.63 1.43 1.87 dNA SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.54 1.37 1.74 e60 SGTF S S 2020-11-01  10 LTLA:date  cc 
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 sgtf 1.64 1.43 1.87 e60 SGTF S S 2020-11-01  10 LTLA:date  ipw 
Misclassification 
adjustment 
              
 p_voc 1.65 1.44 1.88 d28 pVOC S S 2020-09-01  10 LTLA:date  cc 
 p_voc 1.72 1.49 1.99 d28 pVOC S S 2020-09-01  10 LTLA:date  ipw 
 p_voc 1.63 1.44 1.86 d28 pVOC S S 2020-11-01  10 LTLA:date  cc 
 p_voc 1.71 1.48 1.97 d28 pVOC S S 2020-11-01  10 LTLA:date  ipw 
 p_voc 1.60 1.41 1.82 d60 pVOC S S 2020-11-01  10 LTLA:date  cc 




              
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.67 1.46 1.90 d28 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.52 1.36 1.69 d28 SGTF S S 2020-11-01  10 LTLA:week  cc 
 sgtf 1.63 1.44 1.85 d28 SGTF S S 2020-11-01  10 LTLA:week  ipw 
 sgtf 1.49 1.36 1.64 d28 SGTF S S 2020-11-01  10 NHSE:date  cc 
 sgtf 1.47 1.28 1.68 d28 SGTF S S 2020-11-01  10 NHSE:date  ipw 
 sgtf 1.50 1.37 1.65 d28 SGTF S S 2020-11-01  10 NHSE:week  cc 
 sgtf 1.48 1.28 1.70 d28 SGTF S S 2020-11-01  10 NHSE:week  ipw 
 sgtf 1.56 1.39 1.75 d28 SGTF S S 2020-11-01  10 UTLA:date  cc 
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 sgtf 1.56 1.37 1.78 d28 SGTF S S 2020-11-01  10 UTLA:date  ipw 
 sgtf 1.51 1.36 1.67 d28 SGTF S S 2020-11-01  10 UTLA:week  cc 
 sgtf 1.52 1.33 1.74 d28 SGTF S S 2020-11-01  10 UTLA:week  ipw 
Age and IMD 
terms (linear vs. 
spline) 
              
 sgtf 1.58 1.40 1.79 d28 SGTF L L 2020-11-01  10 LTLA:date  cc 
 sgtf 1.68 1.47 1.92 d28 SGTF L L 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.59 1.41 1.80 d28 SGTF L S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.69 1.47 1.93 d28 SGTF L S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.57 1.39 1.78 d28 SGTF S L 2020-11-01  10 LTLA:date  cc 
 sgtf 1.66 1.45 1.89 d28 SGTF S L 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.67 1.46 1.90 d28 SGTF S S 2020-11-01  10 LTLA:date  ipw 
By week since 
specimen 
              
 sgtf 1.26 1.00 1.59 d00-07 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
cc 
 sgtf 1.56 1.17 2.08 d00-07 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
ipw 
 sgtf 1.48 1.22 1.79 d08-14 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
cc 
 sgtf 1.53 1.28 1.83 d08-14 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
ipw 
 sgtf 2.16 1.63 2.85 d15-21 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
cc 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted February 11, 2021. ; https://doi.org/10.1101/2021.02.01.21250959doi: medRxiv preprint 
 sgtf 2.18 1.63 2.91 d15-21 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
ipw 
 sgtf 2.01 1.40 2.88 d22-28 SGTF S S 2020-11-01  10 LTLA:date sgtf_by_w
eek 
cc 





              
 sgtf 1.55 1.37 1.75 d28 SGTF S S 2020-09-01  10 LTLA:date  cc 
 sgtf 1.65 1.44 1.88 d28 SGTF S S 2020-09-01  10 LTLA:date  ipw 
 sgtf 1.55 1.37 1.75 d28 SGTF S S 2020-10-01  10 LTLA:date  cc 
 sgtf 1.65 1.44 1.88 d28 SGTF S S 2020-10-01  10 LTLA:date  ipw 
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date  cc 
 sgtf 1.67 1.46 1.90 d28 SGTF S S 2020-11-01  10 LTLA:date  ipw 
 sgtf 1.62 1.42 1.85 d28 SGTF S S 2020-12-01  10 LTLA:date  cc 
 sgtf 1.69 1.46 1.95 d28 SGTF S S 2020-12-01  10 LTLA:date  ipw 
 sgtf 1.69 1.39 2.04 d28 SGTF S S 2021-01-01  10 LTLA:date  cc 
 sgtf 1.85 1.47 2.32 d28 SGTF S S 2021-01-01  10 LTLA:date  ipw 
 sgtf 1.59 1.41 1.81 d28 SGTF S S LTLA  10 LTLA:date  cc 





              
 sgtf 1.59 1.41 1.80 d28 SGTF L S 2020-11-01  10 LTLA:date age:tstop cc 
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 sgtf 1.68 1.47 1.93 d28 SGTF L S 2020-11-01  10 LTLA:date age:tstop ipw 
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date sex:tstop cc 
 sgtf 1.67 1.46 1.91 d28 SGTF S S 2020-11-01  10 LTLA:date sex:tstop ipw 
 sgtf 1.58 1.39 1.78 d28 SGTF S L 2020-11-01  10 LTLA:date imd:tstop cc 
 sgtf 1.66 1.45 1.90 d28 SGTF S L 2020-11-01  10 LTLA:date imd:tstop ipw 
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date eth:tstop cc 
 sgtf 1.67 1.46 1.90 d28 SGTF S S 2020-11-01  10 LTLA:date eth:tstop ipw 
 sgtf 1.58 1.40 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date res:tstop cc 
 sgtf 1.67 1.46 1.91 d28 SGTF S S 2020-11-01  10 LTLA:date res:tstop ipw 
No registration 
cutoff 
              
 sgtf 1.59 1.42 1.78 d28 SGTF S S 2020-11-01  0 LTLA:date  cc 
 sgtf 1.61 1.42 1.83 d28 SGTF S S 2020-11-01  0 LTLA:date  ipw 
Adjustment for, 
not stratification 
by, region and 
time 
              
 sgtf 1.50 1.37 1.65 d28 SGTF S S 2020-11-02 2020-01-24 10  NHSE:we
ek 
cc 
 sgtf 1.48 1.28 1.71 d28 SGTF S S 2020-11-02 2020-01-24 10  NHSE:we
ek 
ipw 
Subjects with full 
28-day follow-up 
only 
              
 sgtf 1.46 1.22 1.74 d28 SGTF S S 2020-11-01 T - 38 0 LTLA:date  cc 
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 sgtf 1.58 1.39 1.79 d28 SGTF S S 2020-11-01  10 LTLA:date asymptom
atic 
cc 






              
 p_voc 1.64 1.44 1.86 d28 pVOC2 S S 2020-11-01  10 LTLA:date  cc 
 p_voc 1.71 1.48 1.97 d28 pVOC2 S S 2020-11-01  10 LTLA:date  ipw 
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Supplementary Figures 
 
Fig. S1. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by sex.  
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Fig. S2. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by age group. Note that the Y axis differs for each panel.  
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Fig. S3. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by residence. Note that the Y axis differs for each panel.  
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Fig. S4. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by ethnicity.  
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Fig. S5. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by Index of Multiple Deprivation (IMD) decile. 
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Fig. S6. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by NHS region.   
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Fig. S7. Kaplan-Meier plots of survival within 60 days of positive test for SGTF versus 
non-SGTF by specimen date. 
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Fig. S8. Schoenfeld residuals for survival model by SGTF stratified by LTLA and 
specimen date . Model uses linear terms for age and IMD a 28-day followup using complete 
cases. Schoenfeld residual tests give P = 0.031 for SGTF; P = 0.425 for age; P = 0.170 for sex; 
P = 0.603 for IMD decile; P = 0.410 for ethnicity; P = 0.728 for residence type; and P = 0.244 
globally. 
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Fig. S9. Misclassification model. For each NHS England region, we fit a beta-binomial model 
(purple, Modelled SGTF) to the observed SGTF frequencies among Pillar 2 tests (black, 
Observed SGTF), which estimates a constant proportion of “false positive” SGTF samples 
among non-VOC 202012/01 specimens (orange, Modelled non-VOC SGTF) and a logistically 
growing proportion of VOC 202012/01 specimens over time (blue, Modelled VOC). This allows 
us to model the conditional probability that a specimen with SGTF represents VOC 202012/01 
(teal, P(VOC|SGTF)). For our misclassification survival analysis, pVOC = 0 for non-SGTF 
specimens and pVOC = P(VOC|SGTF) for SGTF specimens.  
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Fig. S10. Ct values for SGTF versus non-SGTF. The distribution of Ct values for (a) ORF1ab 
and (b) N gene targets among specimens collected between 1–25 January 2021. 
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Fig. S11. Q-Q plot assessing the fit of the final missingness model (Cauchit link). 
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Fig. S12. Comparison of the proportion of samples with S gene dropout in our Pillar 2 sample 
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